What is Pemvidutide?
An investigational once-weekly GLP-1/glucagon dual agonist studied for obesity and fatty liver disease (MASH).
Pemvidutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
8 registered trials · 3 indexed papers · 4 human / 2 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Pemvidutide is described as Altimmune's balanced 1:1 GLP-1 and glucagon receptor agonist, designed with EuPort technology for slower absorption. (An unrelated cancer drug also used the code ALT-801.)
Its main program is in metabolic dysfunction-associated steatohepatitis (MASH).
Mechanism (as described)
- GLP-1 activity reduces appetite; glucagon activity is described as increasing energy use and liver fat breakdown.
Evidence (as described)
- A 12-week randomized trial reported large reductions in liver fat in MASLD (Harrison et al., J Hepatol 2025).
- The phase 2b IMPACT trial in MASH reported 24-week results in The Lancet (Noureddin et al., 2025).
Status
Investigational (phase 2/3).
Registered human trials (8)
Peer-reviewed studies (3)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study | Noureddin M et al. | Lancet (London, England) | 2025 | Randomized Controlled Trial |
| Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study | Harrison SA et al. | Journal of hepatology | 2025 | Randomized Controlled Trial |
| Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies | Fishman MN et al. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | Clinical Trial, Phase I |
More cited research
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov (2026, human observational)
- Systemic Pharmacokinetic Principles of Therapeutic Peptides (2026, human observational)
- Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis (2022, animal)
Conditions researched
Related compounds
- Cotadutide
- CagriSema (Cagrilintide + Semaglutide)
- Dulaglutide
- Exenatide
- Liraglutide
- VK2735
- ACTH (Corticotropin)
- ANP (Atrial Natriuretic Peptide)
- Alpha-MSH
- Amycretin
FAQ
What is Pemvidutide?
An investigational once-weekly GLP-1/glucagon dual agonist studied for obesity and fatty liver disease (MASH).
How many registered human trials study Pemvidutide?
The PeptideWhiz trial index lists 8 registered trials for Pemvidutide, the most recent from 2026.
How much published research exists on Pemvidutide?
The PeptideWhiz paper index links 3 PubMed papers to Pemvidutide; by study type, 4 human and 2 animal studies.
Which conditions is Pemvidutide researched for?
Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).